Myeloproliferative Neoplasm

In this video, John O. Mascarenhas, MD, highlighted a presentation that explored the science driving clinical development.

John O. Mascarenhas, MD, spoke with Healio about a presentation given during the morning session at 14th International Congress on Myeloproliferative Neoplasms.

In this video, John O. Mascarenhas, MD, provided an overview of his presentation at 14th International Congress on Myeloproliferative Neoplasms that delved into new treatments, specifically focused on myelofibrosis.

The FDA approved pemigatinib for treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms and rearrangement of fibroblast growth factor receptor 1, according to a press release from the agent’s manufacturer.

Aaron T. Gerds, MD, MS, spoke with Healio about the randomized phase 3 MOMENTUM study.

The FDA granted orphan drug designation to TP-3654 for the treatment of myelofibrosis.

Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s European Hematology Association Congress.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

The FDA placed a partial clinical hold on a phase 1 dose-escalation study of a therapy under investigation for certain patients with blood cancer.

SALT LAKE CITY — Socioeconomic disadvantage among hematopoietic stem cell transplant donors appeared associated with poorer outcomes among transplant recipients, according to study results.